RAAFT-2: Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation

Riyaz A Kaba, Douglas Cannie, Omar Ahmed

Abstract


Radiofrequency ablation (RFA) for the treatment of paroxysmal Atrial Fibrillation (pAF) has a class 1 indication in patients who have not tolerated or responded to antiarrhythmic medications. Antiarrhythmic medications (AAM) are, however, limited not only by modest efficacy, but also by significant side effects. Discontinuation rates for AAM range from 11-40% in trials. The RAAFT-2 trial evaluates the use of RFA as a first line treatment for pAF compared to optimal pharmacological management.

Full Text:

PDF

Refbacks

  • There are currently no refbacks.


Copyright (c) 2017 Riyaz A Kaba, Douglas Cannie, Omar Ahmed

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.